Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.65 |
| ▸ | DRD2 | P14416 | 11/20 | 0.65 |
| ▸ | HTR2A | P28223 | 9/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7099291 | 0.99 | HTR1A (0.64) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4890097 | 0.82 | HTR1A (0.73) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL7098770 | 0.81 | HTR1A (0.72) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL10986725 | 0.80 | HTR1A (0.67) | HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL4892386 | 0.80 | HTR1A (0.64) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL7100539 | 0.79 | HTR1A (0.63) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL21485248 | 0.79 | HTR1A (1.00) | HTR1ADRD2HTR2A | |
| SCHEMBL4892696 | 0.76 | HTR1A (0.64) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL4164784 | 0.76 | HTR1A (0.70) | HTR1ADRD2HTR2ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL7098475 | 0.75 | HTR1A (0.63) | HTR1ADRD2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | claimed |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004100954-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0931547-B1 | Piperazinyl-heterocyclic compounds in the treatment of dementia | PFIZER PROD INC (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | SNCA, NLN, INA | HTR1A 76/4885DRD2 355/4885HTR2A 232/4885 |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | HTR1A 79/4885DRD2 199/4885HTR2A 295/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | HTR1A 50/4885DRD2 130/4885HTR2A 80/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | HTR1A 80/4885DRD2 145/4885HTR2A 179/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | HTR1A 126/4885DRD2 255/4885HTR2A 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.